Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
Tamás Constantin,Ivan Foeldvari,Jordi Anton,Joke H. de Boer,Severine Czitrom-Guillaume,Clive Edelsten,Raz Gepstein,Arnd Heiligenhaus,Clarissa Pilkington,Gabriele Simonini,Yosef Uziel,SJ Vastert,Nico M Wulffraat,Anne Mieke J.W. Haasnoot,Karoline Walscheid,Annamária Pálinkás,Reshma Pattani,Zoltán Györgyi,Richárd Kozma,Victor Boom,Andrea Ponyi,Angelo Ravelli,Athimalaipet V Ramanan +22 more
TLDR
Recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for Jia-associated Uveitis patients throughout Europe.Abstract:
Background In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is possibly its most devastating extra-articular manifestation. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience. Consequently, treatment practices differ widely, within and between nations. Objectives To provide recommendations for the diagnosis and treatment of JIA-associated uveitis. Methods Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of nine experienced paediatric rheumatologists and three experts in ophthalmology from Europe. Recommendations derived from a validated systematic literature review were evaluated by an Expert Committee and subsequently discussed at two consensus meetings using nominal group techniques. Recommendations were accepted if >80% agreement was reached (including all three ophthalmologists). Results In total, 22 recommendations were accepted (with >80% agreement among experts): 3 on diagnosis, 5 on disease activity measurements, 12 on treatment and 2 on future recommendations. Conclusions The SHARE initiative aims to identify best practices for treatment of patients suffering from JIA-associated uveitis. Within this remit, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for JIA-associated uveitis patients throughout Europe.read more
Citations
More filters
Journal ArticleDOI
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
Sheila T. Angeles-Han,Sarah Ringold,Timothy Beukelman,Daniel J. Lovell,Carlos Cuello,Mara L. Becker,Robert A. Colbert,Brian M. Feldman,Gary N. Holland,Polly J. Ferguson,Harry Gewanter,Jaime Guzman,Jennifer Horonjeff,Peter A. Nigrovic,Michael J. Ombrello,Murray H. Passo,Matthew L. Stoll,C. Egla Rabinovich,H. Nida Sen,Rayfel Schneider,Olha Halyabar,Kimberly Hays,Amit Aakash Shah,Nancy Sullivan,Ann Marie Szymanski,Marat Turgunbaev,Amy S. Turner,James Reston +27 more
TL;DR: Recommendations for the screening, monitoring, and treatment of uveitis in children with juvenile idiopathic arthritis (JIA) are developed.
Journal ArticleDOI
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
TL;DR: JAK inhibitors may provide a new valuable treatment option in the therapeutic armamentarium for patients affected with JIA-associated uveitis, particularly in those refractory cases that are not adequately responding to conventional or biologic DMARDs.
Journal ArticleDOI
Juvenile idiopathic arthritis
Alberto Martini,Daniel J. Lovell,Salvatore Albani,Hermine I. Brunner,Kimme L. Hyrich,Susan D. Thompson,Nicolino Ruperto +6 more
TL;DR: This Primer by Martini and colleagues summarizes the epidemiology, pathophysiology, diagnosis and management of Juvenile idiopathic arthritis (JIA), the most common chronic inflammatory rheumatic condition of childhood, and reviews future research directions to improve patient care.
Journal ArticleDOI
Update on the epidemiology, risk factors and disease outcomes of juvenile idiopathic arthritis.
TL;DR: The need for adults with JIA to be seen as a distinct group in adult rheumatology practice is important for both service provision and outcome research.
Journal ArticleDOI
Juvenile idiopathic arthritis-associated uveitis.
TL;DR: Two randomised controlled trials of adalimumab in JIA-associated uveitis provide convincing evidence for the use of this biologic in patients who fail to respond adequately to methotrexate.
References
More filters
Journal ArticleDOI
AGREE II: advancing guideline development, reporting and evaluation in health care
Melissa C. Brouwers,Michelle E. Kho,George P. Browman,Jako S. Burgers,Francoise Cluzeau,Gene Feder,Béatrice Fervers,Ian D. Graham,Jeremy M. Grimshaw,Steven E. Hanna,Peter Littlejohns,Julie Makarski,Louise Zitzelsberger +12 more
TL;DR: A strategy was needed to differentiate among guidelines and ensure that those guidelines that vary widely in quality are distinguished.
Journal ArticleDOI
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
Weiya Zhang,M. Doherty,Thomas Bardin,Eliseo Pascual,V. Barskova,P.G. Conaghan,J Gerster,J Jacobs,Burkhard F. Leeb,Frédéric Lioté,Geraldine M. McCarthy,Patrick Netter,George Nuki,Fernando Perez-Ruiz,A Pignone,J. Pimentao,Leonardo Punzi,Edward Roddy,Till Uhlig,Irena Zimmermann-Górska +19 more
TL;DR: 12 key recommendations for management of gout were developed, using a combination of research based evidence and expert consensus, based on a Delphi consensus approach.
Journal ArticleDOI
Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.
TL;DR: This review focuses on recent advances in JIA, especially developments in its classification, validation of appropriate measures of holistic outcome, and the specific contribution of established and newer pharmacologic agents available for treating children and young people.
Journal ArticleDOI
The nominal group as a research instrument for exploratory health studies.
A H Van de Ven,Andre L. Delbecq +1 more
Journal ArticleDOI
Juvenile Idiopathic Arthritis
Angelo Ravelli,Alberto Martini +1 more
TL;DR: Etanercept offers a promising new alternative for patients with JIA who have persistently active arthritis despite treatment with methotrexate, and whether it can be administered safely for long periods of time to children.
Related Papers (5)
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
Sheila T. Angeles-Han,Sarah Ringold,Timothy Beukelman,Daniel J. Lovell,Carlos Cuello,Mara L. Becker,Robert A. Colbert,Brian M. Feldman,Gary N. Holland,Polly J. Ferguson,Harry Gewanter,Jaime Guzman,Jennifer Horonjeff,Peter A. Nigrovic,Michael J. Ombrello,Murray H. Passo,Matthew L. Stoll,C. Egla Rabinovich,H. Nida Sen,Rayfel Schneider,Olha Halyabar,Kimberly Hays,Amit Aakash Shah,Nancy Sullivan,Ann Marie Szymanski,Marat Turgunbaev,Amy S. Turner,James Reston +27 more